Glucocorticoid Signaling and Epigenetic Alterations in Stress-Related Disorders

被引:38
|
作者
Mourtzi, Niki [1 ]
Sertedaki, Amalia [1 ]
Charmandari, Evangelia [1 ,2 ]
机构
[1] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Div Endocrinol Metab & Diabet, Dept Pediat 1,Med Sch, Athens 11527, Greece
[2] Acad Athens, Div Endocrinol & Metab, Biomed Res Fdn, Ctr Clin Expt Surg & Translat Res, Athens 11527, Greece
关键词
stress response; glucocorticoids; epigenetics; stress-related disorders; MINERALOCORTICOID RECEPTOR BLOCKADE; DNA-METHYLATION; GENE PROMOTER; BDNF GENE; MOLECULAR-MECHANISMS; DEPRESSIVE SYMPTOMS; SLC6A4; METHYLATION; EARLY ADVERSITY; BRAIN-FUNCTION; LIFE STRESS;
D O I
10.3390/ijms22115964
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Stress is defined as a state of threatened or perceived as threatened homeostasis. The well-tuned coordination of the stress response system is necessary for an organism to respond to external or internal stressors and re-establish homeostasis. Glucocorticoid hormones are the main effectors of stress response and aberrant glucocorticoid signaling has been associated with an increased risk for psychiatric and mood disorders, including schizophrenia, post-traumatic stress disorder and depression. Emerging evidence suggests that life-stress experiences can alter the epigenetic landscape and impact the function of genes involved in the regulation of stress response. More importantly, epigenetic changes induced by stressors persist over time, leading to increased susceptibility for a number of stress-related disorders. In this review, we discuss the role of glucocorticoids in the regulation of stress response, the mechanism through which stressful experiences can become biologically embedded through epigenetic alterations, and we underline potential associations between epigenetic changes and the development of stress-related disorders.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Epigenetic mechanisms of alcoholism and stress-related disorders
    Palmisano, Martina
    Pandey, Subhash C.
    [J]. ALCOHOL, 2017, 60 : 7 - 18
  • [2] When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders
    Raison, CL
    Miller, AH
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (09): : 1554 - 1565
  • [3] Glucocorticoid mechanisms of functional connectivity changes in stress-related neuropsychiatric disorders
    Hall, Baila S.
    Moda, Rachel N.
    Liston, Conor
    [J]. NEUROBIOLOGY OF STRESS, 2015, 1 : 174 - 183
  • [4] Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders
    Gorzalka, Boris B.
    Hill, Matthew N.
    Hillard, Cecilia J.
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2008, 32 (06): : 1152 - 1160
  • [5] 'Therapyepigenetics': Epigenetic Predictors and Signatures of Treatment Response in Stress-Related Disorders
    Schiele, Miriam
    Salvador, Oscar Crespo
    Koettgen, Anna
    Baune, Bernhard
    Deckert, Juergen
    Domschke, Katharina
    [J]. BIOLOGICAL PSYCHIATRY, 2024, 95 (10) : S41 - S41
  • [6] Hippo Signaling: Emerging Pathway in Stress-Related Psychiatric Disorders?
    Stepan, Jens
    Anderzhanova, Elmira
    Gassen, Nils C.
    [J]. FRONTIERS IN PSYCHIATRY, 2018, 9
  • [7] Parvalbumin interneuron alterations in stress-related mood disorders: A systematic review
    Perlman, George
    Tanti, Arnaud
    Mechawar, Naguib
    [J]. NEUROBIOLOGY OF STRESS, 2021, 15
  • [8] The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
    Fries, Gabriel R.
    Gassen, Nils C.
    Schmidt, Ulrike
    Rein, Theo
    [J]. CURRENT MOLECULAR PHARMACOLOGY, 2016, 9 (02) : 126 - 140
  • [9] An emerging epigenetic framework of systemic and central mechanisms underlying stress-related disorders
    Nasca, Carla
    Rasgon, Natalie
    McEwen, Bruce
    [J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (01) : 235 - 236
  • [10] An emerging epigenetic framework of systemic and central mechanisms underlying stress-related disorders
    Carla Nasca
    Natalie Rasgon
    Bruce McEwen
    [J]. Neuropsychopharmacology, 2019, 44 : 235 - 236